KPRX
Kiora Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.63
+2.94%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
Market Cap
$11.61M
MomentumView details →
1D Return
+2.94%
YTD Return
+32.23%
RSI (14)
51.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
Market Cap
$11.61M
RSI (14)
51.4
MomentumView details →
1D Return
+2.94%
YTD Return
+32.23%
SummaryUpdated Jun 1, 2026
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) is a clinical-stage specialty pharmaceutical company founded in 1998 and headquartered in Salt Lake City, Utah. Originally incorporated as Eyegate Pharmaceuticals, the company rebranded to Kiora Pharmaceuticals in November 2021. The company went public in February 2015 and focuses exclusively on developing innovative therapies for ophthalmic diseases. As a clinical-stage biotechnology firm, Kiora currently generates minimal revenue while investing heavily in research and development of three primary drug candidates targeting various eye conditions.
Similar companies
Latest newsMore news →
Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation an exclusive, sublicensable license to develop, manufacture, and commercialize its KIO-301 product for ophthalmology indications in South Korea, in exchange for a $1.0 million upfront fee, milestone payments, and double-digit royalties.17d agoKiora Pharmaceuticals secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million received upfront, with remaining proceeds contingent on exercise of milestone-based warrants.28d ago